Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1246213-23-9

Post Buying Request

1246213-23-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • N-(2-tert-butyl-5-hydroxy-4-(1-hydroxy-2-methylpropan-2-yl)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide

    Cas No: 1246213-23-9

  • No Data

  • No Data

  • No Data

  • Debye Scientific
  • Contact Supplier

1246213-23-9 Usage

Description

3-Quinolinecarboxamide, N-[2-(1,1-dimethylethyl)-5-hydroxy-4-(2-hydroxy-1,1-dimethylethyl)phenyl]-1,4-dihydro-4-oxois a complex organic compound with a quinoline core and multiple hydroxyl and methyl groups attached to its structure. 3-QuinolinecarboxaMide, N-[2-(1,1-diMethylethyl)-5-hydroxy-4-(2-hydroxy-1,1-diMethylethyl)phenyl]-1,4-dihydro-4-oxois characterized by its unique chemical properties and potential applications in various fields.

Uses

Used in Pharmaceutical Industry:
3-Quinolinecarboxamide, N-[2-(1,1-dimethylethyl)-5-hydroxy-4-(2-hydroxy-1,1-dimethylethyl)phenyl]-1,4-dihydro-4-oxois used as an impurity in the drug Ivacaftor (I940600) for the treatment of cystic fibrosis. Its presence in the drug may affect the efficacy and safety of the treatment, making it crucial to monitor and control its levels during the drug manufacturing process.
Used in Chemical Research:
3-QuinolinecarboxaMide, N-[2-(1,1-diMethylethyl)-5-hydroxy-4-(2-hydroxy-1,1-diMethylethyl)phenyl]-1,4-dihydro-4-oxocan also be used as a starting material or intermediate in the synthesis of other complex organic molecules, particularly those with potential applications in the pharmaceutical, agrochemical, or materials science industries. Its unique structure and functional groups make it a valuable candidate for further research and development.
Used in Quality Control:
In the context of drug manufacturing, 3-Quinolinecarboxamide, N-[2-(1,1-dimethylethyl)-5-hydroxy-4-(2-hydroxy-1,1-dimethylethyl)phenyl]-1,4-dihydro-4-oxocan be used as a reference compound for quality control purposes. By comparing the properties and behavior of this compound with those of the active pharmaceutical ingredient, manufacturers can ensure the consistency and quality of the final product.

Check Digit Verification of cas no

The CAS Registry Mumber 1246213-23-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,4,6,2,1 and 3 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1246213-23:
(9*1)+(8*2)+(7*4)+(6*6)+(5*2)+(4*1)+(3*3)+(2*2)+(1*3)=119
119 % 10 = 9
So 1246213-23-9 is a valid CAS Registry Number.

1246213-23-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name N-[2-tert-butyl-5-hydroxy-4-(1-hydroxy-2-methylpropan-2-yl)phenyl]-4-oxo-1H-quinoline-3-carboxamide

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1246213-23-9 SDS

1246213-23-9Downstream Products

1246213-23-9Relevant articles and documents

Altering metabolic profiles of drugs by precision deuteration 2: Discovery of a deuterated analog of ivacaftor with differentiated pharmacokinetics for clinical development

Harbeson, Scott L.,Morgan, Adam J.,Liu, Julie F.,Aslanian, Ara M.,Nguyen, Sophia,Bridson, Gary W.,Brummel, Christopher L.,Wu, Lijun,Tung, Roger D.,Pilja, Lana,Braman, Virginia,Uttamsingh, Vinita

, p. 359 - 367 (2017)

Ivacaftor is currently used for the treatment of cystic fibrosis as both monotherapy (Kalydeco; Vertex Pharmaceuticals, Boston, MA) and combination therapy with lumacaftor (Orkambi; Vertex Pharmaceuticals). Each therapy targets specific patient population

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

-

Page/Page column 49-50, (2010/10/03)

This invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R is COOH or CH2OH.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1246213-23-9